Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PepGen Inc. (PEPG) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, PepGen uses current reports on Form 8-K, registration statements, and other filings to report material events related to its clinical-stage biotechnology business.
Through these filings, investors can review Form 8-K reports covering topics such as financial results for recent quarters, material financing transactions, executive appointments, equity compensation changes, and investor communications. For example, PepGen has filed 8-Ks announcing quarterly financial results, the launch and pricing of an underwritten public offering under a shelf registration statement on Form S-3, and the appointment of a Chief Business and Legal Officer. Other 8-Ks describe an option repricing for employee stock options under the company’s 2020, 2022, and 2024 equity plans, and the furnishing of updated corporate presentations and clinical data summaries.
Filings also confirm that PepGen’s common stock, par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Global Select Market under the symbol PEPG. Registration statements and prospectus supplements referenced in the filings outline how the company issues shares to fund its Enhanced Delivery Oligonucleotide (EDO) platform and clinical programs, including the FREEDOM-DM1 and FREEDOM2-DM1 trials of PGN-EDODM1 in myotonic dystrophy type 1.
On Stock Titan, these SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as new financings, changes in executive leadership, or updates to clinical and investor presentations. Real-time updates from EDGAR, combined with AI explanations of complex legal and financial language, allow investors to follow PepGen’s regulatory history, capital-raising activities, and material corporate events without reading every line of each filing.
PepGen Inc. executive Paul Streck, EVP and Head of R&D, reported awards of equity-based compensation. He received stock options covering 196,500 shares at an exercise price of $0.00 per share and 50,300 shares of common stock in the form of restricted stock units. The RSUs vest in equal annual installments over four years starting on March 1, 2027, while the option vests 25% on the one-year anniversary of the grant date and the remaining 75% in 36 equal monthly installments, in each case conditioned on continued service.
PepGen Inc. reported that Chief Financial Officer Noel Donnelly received new equity awards. On March 1, 2026, he was granted a stock option for 300,000 shares at a price of $0.00 per share, classified as a grant or award acquisition. The option vests with 25% on the one-year anniversary of the grant date and the remaining 75% in 36 equal monthly installments, contingent on continued service.
On the same date, he also received 76,793 restricted stock units, each representing one share of common stock upon vesting. These RSUs vest in equal annual installments over four years starting March 1, 2027, subject to his continued service. Following these awards, his directly held common stock increased to 113,687 shares, which includes 11,938 shares acquired under the 2022 Employee Stock Purchase Plan on November 28, 2025.
PepGen Inc.’s President and CEO James G. McArthur received new equity awards. On March 1, 2026, he was granted a stock option for 731,250 shares of PepGen common stock at an exercise price of $0.0000 per share, all held directly.
He also received 187,688 restricted stock units, each representing one share of common stock upon vesting. These RSUs vest in four equal annual installments starting on March 1, 2027, while the stock option vests 25% on the one-year anniversary of the grant date and the remaining 75% in 36 equal monthly installments, all subject to his continued service.
PepGen Inc. reported a change to stock option grants held by its Executive Vice President and Head of R&D. On November 4, 2025, the board approved a repricing of this officer’s outstanding stock options granted under PepGen’s 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with the prior higher exercise prices, such as $9.83, remaining in place if conditions are not met.
The lower exercise price applies only if the officer satisfies a specified retention period; otherwise, the original exercise price will continue to apply. One of the options described vests 25% on the one-year anniversary of its grant date, with the remaining 75% vesting in 36 equal monthly installments, contingent on continued service or employment with the company at each vesting date.
PepGen Inc. reported a change to its President and CEO’s stock option grants. On November 4, 2025, the board approved a repricing of the executive’s outstanding stock options granted under the company’s 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, while all other terms of the options remain the same, except that the lower exercise price applies only if the executive satisfies a required retention period; otherwise, the original higher exercise prices will continue to apply.
The affected options, which are rights to buy PepGen common stock, generally vest over four years. For these grants, 25% of the shares vest on the first anniversary of the applicable vesting commencement or grant date, with the remaining shares vesting in 36 equal monthly installments, subject to continued service or employment on each vesting date.
PepGen Inc. disclosed that its Board of Directors approved a repricing of the Chief Financial Officer’s outstanding stock options on November 4, 2025. Several existing stock option grants with exercise prices of $10.88, $12, $15.25, and $16.62 were canceled and replaced with options at a new exercise price of $4.53, while keeping other terms the same. The reduced exercise price applies only if the CFO satisfies an applicable retention period; otherwise, the original higher exercise prices will continue to apply.
The affected options cover multiple grants under PepGen’s 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan, with expirations between November 10, 2031 and February 28, 2034. The filing notes that one grant vests over four years from an October 15, 2021 vesting start date, and others vest 25% after one year with the balance vesting in 36 equal monthly installments, all contingent on continued service.
PepGen Inc. reported that on December 8, 2025 it appointed Joseph Vittiglio, Esq. as its Chief Business and Legal Officer. This new executive role combines responsibility for the company's business functions with oversight of legal affairs, adding depth to its leadership team. The company also furnished a related press release as Exhibit 99.1 providing additional detail on the appointment.
PepGen Inc. (PEPG) reported it furnished a press release announcing financial results for the quarter ended September 30, 2025. The company disclosed this under Item 2.02 (Results of Operations and Financial Condition), noting the release is provided as Exhibit 99.1.
The exhibit is furnished, not filed, which affects how it is incorporated by reference. PepGen’s common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The 8-K was signed by CFO Noel Donnelly.
PepGen Inc. (PEPG) reported Q3 results and strengthened liquidity following a September equity raise. The company ended September 30, 2025 with $163.7 million in cash, cash equivalents and marketable securities. Q3 net loss was $18.0 million (basic and diluted loss per share $0.52), driven by research and development expense of $13.4 million and general and administrative expense of $5.2 million.
In September 2025, PepGen completed an underwritten public offering, issuing 35,937,500 shares (including the underwriters’ option) for net proceeds of $107.6 million. With the improved cash position, management concluded that conditions raising substantial doubt about continuing as a going concern no longer exist and believes current resources will fund operations for at least 12 months; elsewhere the company indicates funding into the second half of 2027.
Clinical updates included PGN‑EDODM1 for DM1: the FREEDOM Phase 1 single‑dose study’s 15 mg/kg cohort showed a mean splicing correction of 53.7% and was generally well tolerated. Dose escalation will conclude at 15 mg/kg. The Phase 2 FREEDOM2 multiple‑dose study is open in Canada and the U.K., with initial 5 mg/kg cohort data expected in Q1 2026. Development of PGN‑EDO51 for DMD was discontinued in May 2025. Shares outstanding were 68,748,224 as of November 5, 2025.
PepGen Inc. approved a company‑wide repricing of underwater employee stock options, effective November 4, 2025. Eligible options under the 2020, 2022 and 2024 plans now carry a new exercise price of $4.53. To use the reduced price, employees must remain in service through a defined retention period that ends on the earliest of March 31, 2027 or a qualifying sale event under the applicable plan.
The repricing covers 3,557,903 option shares that previously had exercise prices ranging from $8.89 to $17.91. The Board approved the change on the recommendation of the Compensation Committee; CEO James McArthur recused himself from the vote as an interested director. The company states the goal is to retain and motivate employees during a critical stage, noting that approximately two‑thirds of employee options were underwater at approval.